A newswire release distributed through GlobeNewswire says a review of the US supplier Kylo Peptides sets a standard for how research peptide vendors should document what they sell. The release was issued from Sheridan, Wyoming, and does not name who conducted the review.

The documents at the center of it are Certificates of Analysis, or COAs, which report the test results for a given material. A lot-specific COA ties those results to one production batch by lot number, so a buyer can match the paperwork to the vial in front of them rather than to some unidentified sample.

The number worth noticing

The strongest fact in the release is not about Kylo at all. A 2026 analysis of thousands of research peptide samples found that fewer than six in ten met both purity and label-accuracy thresholds, and 156 samples did not contain the stated peptide at all.

The release attributes that context to the regulatory squeeze as well: in September 2023 the FDA placed several peptides in Category 2 of its interim 503A bulk substances list, a group it says may present significant safety risks in compounding. That, the release argues, pushed more buyers toward research-use compounds sold online, where testing is reported inconsistently.

Four labs, seven assays

Kylo says every batch ships with a public, lot-matched COA, with past COAs kept in a public library. Purity of 99 percent or higher is measured by HPLC, which separates a sample and reports how much of the intended peptide is present, and identity is confirmed by LC-MS, which weighs the molecule against the label.

Testing runs across four named independent laboratories, Janoshik, Freedom Diagnostics, Vanguard Laboratory and Optiq Health Labs, across seven assays after an in-house check. All four are described as accredited to ISO/IEC 17025, the international standard for testing laboratory competence and impartiality.

The unnamed reviewer

Every one of those figures originates with the company or with a review the release declines to attribute. No independent verification of the purity claims appears anywhere in the document, and the spokesperson quoted, Susane Williams, works for Kylo.

Bottom line

The underlying argument is sound and unusually specific: a purity claim means nothing without a dated, lot-numbered document a buyer can open before ordering. That standard is worth applying to this release too.